Compare Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Tax Managed Fund FTSE Developed Markets ETF vs Zoetis Inc — how do they compare? Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.35 (market cap $323.80B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 10.7× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days and Zoetis Inc for 70 Days on average.
| VEA | ZTS | |
|---|---|---|
Market Cap | $323.80B | $30.20B |
Volume | 17,001,112 | 6,175,327 |
52-Week High | $73.79 | $147.53 |
52-Week Low | $58.90 | $69.09 |
Typical Hold Time | 131 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VEA trades at $69.86, down 0.57% on the day, with a bearish technical signal from moving averages and oscillators. The ETF's low expense ratio of 0.03% and focus on developed markets outside the U.S. are key attributes, though financial ratios are not disclosed in the provided data. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing positions while others reduced stakes.
The outlook for VEA is mixed, with technical indicators suggesting near-term pressure, but its cost efficiency and dividend yield offer long-term value. Risks include market volatility and economic shifts in developed economies. Investors should weigh the bearish technicals against the fund's structural advantages in a diversified portfolio.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
